Carbiotix summarizes activities during Q1 - positive progress and interest for CarbiAXOS
Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company sees positive progress with regards to meeting LinkGut partner targets and a growing interest in the CarbiAXOS nutraceutical ingredient in preparation for the 2022 product launch. During Q1 2022, Carbiotix rolled-out one new LinkGut partner based in Sweden, signed one new LinkGut agreement and grew the prospect pipeline to ten potential partners globally, with six partners under agreement review. In preparation for the upcoming launch of CarbiAXOS, the Company received qualified expressions of interest from ten potential customers to receive samples for testing and product formulation activities.
Kristofer Cook, CEO of Carbiotix, comments
"I am very happy to announce this positive progress towards meeting our LinkGut partner targets, and the growing interest in our CarbiAXOS nutraceutical ingredient in preparation for the 2022 product launch. Our LinkGut white label, API, B2B gut health testing service is a leading service with regards to value for money, reliability and flexibility. The growing number of prospects, newly signed partner and service roll-out are testimony that LinkGut is a highly competitive offering and that the service has the potential to play a key role in supporting our modulator sales within the Smart Prebiotic concept we are promoting. Today we have four signed agreements, two partner roll-outs in place, and ten qualified prospects with six at the stage of agreement review.
This is the first quarter we have communicated the customer prospect pipeline with regards to CarbiAXOS. I am very happy to see a healthy and growing level of interest to receive samples for testing and product formulation activities, now numbering ten potential customers, with each prospect at a different level of maturity with regards to becoming a customer. This pipeline will be used to continually gauge customer interest and maturity, and thus help guide our planning activities with regards to production capacity expansion. CarbiAXOS nutraceutical ingredient will be first sold to manufacturers of products targeting the US market, with a planned launch in 2022.”
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 7 April 2022.
Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Carbiotix AB
Kristofer Cook, CEO
Tel: +46 (0)708-796580
E-mail: kristofer.cook@carbiotix.com
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.